XTL Biopharmaceuticals Ltd ADR (XTLB) - Total Assets
Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) holds total assets worth $8.55 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See XTLB net assets for net asset value and shareholders' equity analysis.
XTL Biopharmaceuticals Ltd ADR - Total Assets Trend (2001–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd ADR's total assets have evolved over time, based on quarterly financial data.
XTL Biopharmaceuticals Ltd ADR - Asset Composition Analysis
Current Asset Composition (December 2024)
XTL Biopharmaceuticals Ltd ADR's total assets of $8.55 Million consist of 15.7% current assets and 84.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.3% |
| Accounts Receivable | $99.00K | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.82 Million | 44.6% |
| Goodwill | $3.19 Million | 37.4% |
Asset Composition Trend (2001–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XTLB market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XTL Biopharmaceuticals Ltd ADR's current assets represent 15.7% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2024, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 44.6% of total assets.
XTL Biopharmaceuticals Ltd ADR Competitors by Total Assets
Key competitors of XTL Biopharmaceuticals Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
XTL Biopharmaceuticals Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.61 | 11.43 | 33.03 |
| Quick Ratio | 0.61 | 11.43 | 33.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-867.00K | $2.33 Million | $6.21 Million |
XTL Biopharmaceuticals Ltd ADR - Advanced Valuation Insights
This section examines the relationship between XTL Biopharmaceuticals Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 1.03 |
| Asset Growth Rate (YoY) | 252.4% |
| Total Assets | $8.55 Million |
| Market Capitalization | $8.80 Million USD |
Valuation Analysis
Above Book Valuation: The market values XTL Biopharmaceuticals Ltd ADR's assets above their book value (1.03x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: XTL Biopharmaceuticals Ltd ADR's assets grew by 252.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for XTL Biopharmaceuticals Ltd ADR (2001–2024)
The table below shows the annual total assets of XTL Biopharmaceuticals Ltd ADR from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.55 Million | +252.43% |
| 2023-12-31 | $2.43 Million | -42.04% |
| 2022-12-31 | $4.19 Million | -36.75% |
| 2021-12-31 | $6.62 Million | +1.77% |
| 2020-12-31 | $6.50 Million | -9.83% |
| 2019-12-31 | $7.21 Million | -15.90% |
| 2018-12-31 | $8.57 Million | +30.20% |
| 2017-12-31 | $6.59 Million | +118.30% |
| 2016-12-31 | $3.02 Million | -43.32% |
| 2015-12-31 | $5.32 Million | -5.69% |
| 2014-12-31 | $5.64 Million | -29.58% |
| 2013-12-31 | $8.02 Million | -27.70% |
| 2012-12-31 | $11.09 Million | +172.18% |
| 2011-12-31 | $4.07 Million | +7.27% |
| 2010-12-31 | $3.80 Million | +431.05% |
| 2009-12-31 | $715.00K | -79.15% |
| 2008-12-31 | $3.43 Million | -75.72% |
| 2007-12-31 | $14.13 Million | -47.48% |
| 2006-12-31 | $26.90 Million | +77.55% |
| 2005-12-31 | $15.15 Million | -40.87% |
| 2004-12-31 | $25.62 Million | +3.10% |
| 2003-12-31 | $24.85 Million | -35.32% |
| 2002-12-31 | $38.42 Million | -30.27% |
| 2001-12-31 | $55.11 Million | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more